← Eichor
Study identifier: NCT07179614 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Kentucky Women's Justice Community Overdose Innovation Network - Phase II

Condition: Overdose Risk · Opioid Use Disorder · Stimulant Use Disorders  ·  Sponsor: Michele Staton

PhaseNA
Planned participants300
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersYes

About this study

This project continues our work with women in the Kentucky Women's Justice Community Overdose Innovation Network Phase II (WJCOIN-II) with the overall aim of reducing overdose risk during the transition from jail to rural communities. WJCOIN-II has potential for significant impact regarding the effectiveness, implementation, and sustainability of innovative overdose prevention strategies during the high-risk time of community re-entry among vulnerable, CLS-involved women in rural communities. This research will impact the field by increasing the capacity of the criminal legal system to respond to the overdose crisis through increased access to prevention strategies to reduce overdose risk.

This description comes directly from the study's public registry record.

Talk to the study team

Michele Staton, PhD  ·  859-312-8245  ·  mstaton@uky.edu

Martha Tillson, PhD  ·  859-447-5007  ·  martha.tillson@uky.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Harlan County Detention CenterHarlan, Kentucky, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07179614